Elegen and GSK entered a collaboration and licensing agreement for the use of Elegen’s cell-free DNA manufacturing technology in the development of GSK’s vaccines and medicines.
 
The terms of the agreement include upfront fees and purchase commitments of Elegen’s ENFINIA DNA to support GSK’s development of medicines and vaccines, including RNA vaccines. Elegen is also eligible to receive milestone payments relating to the development of new product features and a potential equity investment in Elegen by GSK.
 
ENFINIA DNA delivers NGS-verified, high-complexity, clonal-quality, linear DNA up to 7kb in as fast as seven business days, according to the company. Unlike conventional synthesis of mRNA from linearized plasmid DNA, Elegen’s DNA is produced entirely cell-free, with the potential to enable a seamless transition from discovery to clinical scale-up under GMP. 
 
“Over the past year dozens of customers, including multiple top 10 biopharma, have validated the unprecedented speed, length, accuracy and complexity of our cell-free DNA manufacturing technology,” said Matthew Hill, Ph.D., Elegen founder and CEO. “GSK recognizes the importance of a reliable, turnkey supply of DNA for a variety of applications for which speed, accuracy and quality of DNA synthesis are essential. This collaboration will expand our offering to include the clinical production of genetic medicines potentially including mRNA, cell and viral gene therapies.”